77
Participants
Start Date
August 12, 2011
Primary Completion Date
May 28, 2014
Study Completion Date
May 18, 2016
5-Fluorouracil (5-FU)
Participants will receive 5-FU 400 mg per meter-squared (mg/m\^2) IV dose on Day 1 of each 2 weeks' cycle followed by 2400 mg/m\^2, continuous infusion over 46 hours up to 12 cycles.
Bevacizumab
Participants will receive 5 mg/kg bevacizumab IV dose on Day 1 of each 2 weeks' cycle up to Cycle 5 and thereafter cycles 7 to 12; followed by maintenance therapy of 5 mg/kg IV every 2 weeks up to 52 weeks (26 cycles).
Levofolinic acid
Participants will receive levofolinic acid 200 mg/m\^2 IV infusion over 2 hours on Day 1 of each 2 weeks' cycle up to 12 cycles.
Oxaliplatin
Participants will receive oxaliplatin 85 mg/m\^2 IV infusion over 2 hours on Day 1 of each 2 weeks' cycle up to 12 cycles.
Irccs Ospedale San Raffaele;Oncologia Medica, Milan
Irccs Istituto Europeo Di Oncologia (IEO); Oncologia Medica, Milan
Asst Grande Ospedale Metropolitano Niguarda; Dipartimento Di Ematologia Ed Oncologia, Milan
Azienda Ospedaliera Sant' Antonio Abate; Divisione di Oncologia, Gallarate
Fondazione IRCCS Policlinico San Matteo, Pavia
Azienda Ospedaliero-Universitaria S.Orsola-Malpighi; Unità Operativa Oncologia Medica, Bologna
A.O. Universitaria Policlinico Di Modena; Ematologia, Modena
Ospedali Riuniti Di Ancona; Oncology, Ancona
IRCCS Istituto Nazionale Tumori Fondazione Pascale; Oncologia Medica A, Napoli
Az Ospedaliera Nuovo Garibaldi Quartiere Nesima; Oncologia Medica, Catania
Centro Catanese Di Oncologia; Oncologia Medica, Catania
Hoffmann-La Roche
INDUSTRY